The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1

Nature

Volumn 543, Issue 7647, 2017, Pages 733-737

  Wylie, Andrew A ^a   Schoepfer, Joseph ^b   Jahnke, Wolfgang ^b   Cowan Jacob, Sandra W ^b   Loo, Alice ^a   Furet, Pascal ^b   Marzinzik, Andreas L ^b   Pelle, Xavier ^b   Donovan, Jerry ^a   Zhu, Wenjing ^a   Buonamici, Silvia ^a   Hassan, A Quamrul ^a   Lombardo, Franco ^a   Iyer, Varsha ^b   Palmer, Michael ^a   Berellini, Giuliano ^a   Dodd, Stephanie ^a   Thohan, Sanjeev ^a   Bitter, Hans ^a   Branford, Susan ^c   Ross, David M ^d   Hughes, Timothy P ^e   Petruzzelli, Lilli ^a   Vanasse, K Gary ^a   Warmuth, Markus ^a,f   Hofmann, Francesco ^b   Keen, Nicholas J ^a   Sellers, William R ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d SA Pathology   (Australia)

^e SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^f EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCIMINIB; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; NICOTINAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CATALYSIS; DISEASE CONTROL; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITOR; MUTATION; RODENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOSTERISM; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME CONFORMATION; HUMAN; NONHUMAN; PENNSYLVANIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TUMOR XENOGRAFT; ALLOSTERIC SITE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOUSE; MUTATION; PATHOLOGY;

PENNSYLVANIA; PHILADELPHIA; UNITED STATES;

MUS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CATALYTIC DOMAIN; CELL PROLIFERATION; DASATINIB; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTATION; NIACINAMIDE; PYRAZOLES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018402656     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21702     Document Type: Article

References (20)

1. Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123-1132 (2015).
2. Kantarjian, H. M., Baccarani, M., Jabbour, E., Saglio, G. & Cortes, J. E. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin. Cancer Res. 17, 1674-1683 (2011).
3. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029-1035 (2010).
4. Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515-522 (2013).
5. Adrián, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102 (2006).
6. Jahnke, W. et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc. 132, 7043-7048 (2010).
7. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
8. Hantschel, O. et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857 (2003).
9. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
10. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
11. Manley, P. W. et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 445-453 (2010).
12. Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015).
13. Ottmann, O. G. et al. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood 126, 138 (2015).
14. Tanaka, C. et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 87, 197-203 (2010).
15. Kunkel, T. A. & Bebenek, K. DNA replication fidelity. Annu. Rev. Biochem. 69, 497-529 (2000).
16. Al-Kali, A. et al. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117, 327-335 (2011).
17. Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30, 232-238 (2012).
18. Branford, S. et al. Prognosis for patients with CML and > 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124, 511-518 (2014).
19. Hanfstein, B. et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26, 2096-2102 (2012).
20. Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).